ClinicalTrials.gg
CompletedNCT00828971MERAKUpdated Dec 8, 2014

A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs

A Phase 3 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Amoxicilline/clavulanic in Infectious Diseases, sponsored by Bayer. Completed at 22 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-08.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Communicable Diseases with a site in Italy — 9 open to participants now, 10 under way, none of them phase 3. Communicable Diseases · Italy.

Started
2008
the only one that year
Phase 3
Only one
of the 21
Registered
1st of 21
by date
Lead sponsor
1 of 21
Bayer

Among the 21 studies in Communicable Diseases with a site in Italy, this one is the only one that started in 2008, is the only one in phase 3, and was the 1st registered.

Communicable Diseases

627 studies on the registry are indexed under Communicable Diseases; 128 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

9 of the 21 studies in Communicable Diseases with a site in Italy are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Communicable Diseases with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this study is to assess if a therapy with intravenous and oral moxifloxacin is as effective as a therapy with intravenous and oral amoxicilline/clavulanate in the treatment of complicated skin and skin structure infection.

03

Conditions studied

  • Infectious Diseases

Browse trials for

Keywords

  • Complicated skin and skin structure infections
  • cSSSI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Men or women of age >/= 18 years with a diagnosis of bacterial skin and skin structure infection that requires

    • Hospitalization
    • Initial parenteral therapy for at least 48 hours
  • Complicated by at least one of the following criteria:

    • Involvement of deep soft tissues (e.g. fascial, muscle layers)
    • Requirement for a significant surgical intervention including surgical drainage, drainage procedure guided by imaging and/or debridement
    • Association with a significant underlying disease that may complicate response to treatment.
    • Presence of SIRS (Systemic Inflammatory Response Syndrome) defined as two or more of the following signs or symptoms: - temperature > 38.3°C or \< 36°C - white blood cell count > 12.000/mmc or \< 4.000 or > 10% bands - pulse rate > 90 beats/min - respiratory rate > 20178 - systolic blood pressure \</= 90 mmgHg - decreased capillary refill/mottling > 2 seconds - lactate > 2 mmol/L - altered mental status - hyperglycemia > 120 mg/dl or 7.7 mmol/L in the absence of diabetes - protein C (CPR) > 20 mg/L (VR 0-5)3. Duration of infection \< 21 days
  • Diagnosis of one of the following skin and skin structure infections:

    • major abscess(es) associates with extensive cellulitis
    • erysipelas and cellulitis
    • infected pressure ulcers(s)
    • wound infections including: post surgical (surgical incision), post traumatic, human bite/clenched fist and animal bite wound and wound associated with injection drug abuse
    • Infected ischemic ulcers with at least one of the following conditions: - Diabetes mellitus - Peripheral vascular disease - Conditions pre-disposing to pressure scores such as paraplegia or peripheral neuropathy
  • Presence of at least 3 of the following local signs and symptoms

    • purulent drainage or discharge
    • erythema extended >1 cm from the wound edge
    • fluctuance
    • pain or tenderness to palpation
    • swelling or induration
    • fever defined as body temperature > 37.5°C (axillary), > 38°C (orally), > 38.5°C (tympanically), or > 39°C (rectally). OR Elevated total peripheral white blood cell (WBC) count> 12,000/mm3 OR > 15% immature neutrophils (blends) regardless of total peripheral WBC count
    • C-reactive protein (CRP) >20 mg/L

Exclusion criteria

Exclusion Criteria:

  • Women, who are pregnant or lactating, or in whom pregnancy can not be excluded (Note: a urine pregnancy test has to be performed for all women of before randomization to the study drug).
  • The following skin and skin structure infections:

    • Necrotizing fasciitis including Fournier's gangrene, ecthyma gangrenosum, streptococcal necrotizing fasciitis and clostridial necrotizing fasciitis.
    • Burn wound infections.
    • Secondary infections of a chronic skin disease (eg, atopic dermatitis).
    • Infection of prosthetic materials. Subjects with removal of a prosthetic device involved in an infection should not be included.
    • Infections where a surgical procedure alone is definitive therapy.
    • Subjects with uncomplicated skin and skin structure infections including
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Avelox (Moxifloxacin, BAY12-8039)

  • Active comparator
    Arm 2

    Drug: Amoxicilline/clavulanic

Interventions

  • Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.

  • DrugAmoxicilline/clavulanic

    IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days

06

What researchers measure

Primary outcomes

  1. Clinical response up to 14-21 days after the completion of study drug therapy (Test-of-Cure visit [TOC]).

    Time frame: Test-of-Cure visit [TOC].

Secondary outcomes

  1. Clinical response assessed by the investigator on treatment Day 3-5

    Time frame: Day 3-5

  2. Clinical response assessed by the investigator at the end-of-therapy (EOT).

    Time frame: At the end-of-therapy (EOT)

  3. Time to switch from oral to IV therapy

    Time frame: Day of switch from oral to IV therapy

  4. Bacteriological response (for microbiologically valid population) at the EOT and TOC

    Time frame: At the end-of-therapy (EOT), Test-of-Cure visit [TOC].

07

Study locations

22 sites
  • Bagno di Ripoli, Firenze 50100, Italy
  • Bari, 70124, Italy
  • Bergamo, 24128, Italy
  • Bologna, 40138, Italy
  • Brescia, 25123, Italy
  • Ferrara, 44100, Italy
  • Firenze, 50139, Italy
  • Foggia, 71100, Italy
  • Genova, 16132, Italy
  • Mantova, 46100, Italy
  • Messina, 98158, Italy
  • Napoli, 80131, Italy
  • Padova, 35128, Italy
  • Perugia, 06122, Italy
  • Reggio Emilia, 42100, Italy
  • Rimini, 47900, Italy
  • Roma, 00149, Italy
  • Roma, 00168, Italy
  • Torino, 10149, Italy
  • Udine, 33100, Italy
  • Varese, 21100, Italy
  • Verona, 37126, Italy
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Sep 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2009
First posted
Jan 26, 2009
Start
Nov 2008
Primary completionActual
Sep 2009
CompletionActual
Oct 2009
Last update
Dec 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00828971
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 26, 2009
Start date
Nov 2008
Primary completion
Sep 2009
Completion
Oct 2009
Last update
Dec 8, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion